Treatment of hidradenitis with JAK inhibitors

A technology for inhibitors and hidradenitis suppurativa, applied in medical preparations containing active ingredients, pharmaceutical formulas, drug combinations, etc., can solve unsatisfied, good and other problems, and achieve the effect of improving HiSCR scores

Pending Publication Date: 2022-06-24
PFIZER INC
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Thus, a significant number of patients with moderate to severe HS (approximately 40%) do not respond to treatment with adalimumab, and thus there remains a gap for an effective, safe, and well-tolerated treatment for patients with moderate to severe HS. unmet needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0198] Hidradenitis Suppuratitis Clinical Response (HiSCR)

[0199] This study is ongoing to provide data on efficacy, safety, tolerability and pharmacokinetics of the therapeutic agents being tested in the oral treatment of moderate to severe HS. The maximum duration of the study will be approximately 26 weeks. This includes a screening period of up to 6 weeks, a dosing period of 16 weeks, and a follow-up period of 4 weeks. The study will enroll approximately 192 participants in total (expected to provide approximately 156 completers). After the screening period, participants who met eligibility criteria at the baseline visit will be randomly assigned to receive 1 of 6 treatments. One oral dose level of each therapeutic agent will be investigated: [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazole -4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone (45 mg QD) and (1r,3r)-3- (cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]py...

Embodiment 2

[0202] Lesion count

[0203] Number of inflammatory and non-inflammatory nodules, abscesses, draining and non-draining fistulas, and hypertrophic scars, and physical location (right / left axilla, right / left under breast, breast room, right / left buttock, right / left groin Femoral folds, perianal, perineal, others) will be assessed according to standards in the art.

Embodiment 3

[0205] Abscess count

[0206] The number of abscesses (variable, with or without drainage, tenderness or pain) will be counted at each site as defined above.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods of treating hidradenitis suppurativa using compounds and analogs that inhibit certain kinases, including Janus kinase (JAK).

Description

technical field [0001] The present invention provides methods of treating hidradenitis suppurativa using compounds and analogs that inhibit certain kinases, including Janus kinase (JAK). Background technique [0002] Protein kinases are a family of enzymes that catalyze the phosphorylation of specific residues in proteins, and are broadly divided into tyrosine kinases and serine / threonine kinases. Inappropriate kinase activity caused by mutation, overexpression or inappropriate regulation, dysregulation or deregulation, and overproduction or underproduction of growth factors or cytokines has been implicated in many diseases, including but not limited to cancer, cardiovascular disease , allergies, asthma and other respiratory diseases, autoimmune diseases, inflammatory diseases, bone diseases, metabolic and neurological and neurodegenerative disorders such as Alzheimer's disease. Inappropriate kinase activity triggers a variety of biological cellular responses involving cell...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4985A61K31/506A61K31/519A61P17/00
CPCA61K31/506A61K31/519A61K31/4985A61P17/00
Inventor A·芬索姆B·S·格尔斯腾伯格D·R·欧文
Owner PFIZER INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap